ABSTRACT. Calcitonin (CT) has been shown to have various functions including osteoclast activity and calcium and phosphorus metabolism in mammals. In the present study, we measured the amounts of CT mRNA in the mouse brain, liver, kidney, heart and testis at various development stages, 14 days post-coitum (dpc), 17-dpc, newborn, 1 week and 8 weeks (adult), using real-time PCR. In the brain and kidney, the amount of CT mRNA decreased with development. In the testis, elevated amounts were observed at 17-dpc and 8 weeks. In the liver, the amount increased from the 14 dpc embryo to newborn stage and then decreased. In the heart, elevated amounts were observed at 17-dpc. Additionally, the CT antisense transcript was determined using a modified RT-PCR and nucleotide sequencing in the present study. Organs with high mRNA expressions were examined for localization of transcripts using in situ hybridization. The CT sense and antisense transcripts in the 14 dpc brain were mainly localized in the mesencephalon. In the pre-and postnatal stages, sense and antisense transcripts were shown to exist rather uniformly in the kidney, heart, liver and testis. In the 17-dpc rib and thyroid lobe and the adult ovary, the sense and antisense transcripts were found to be densely localized. KEY WORDS: calcitonin, in situ hybridization, mouse, sense/antisense transcripts.
Calcitonin (CT) is a 32 amino acid peptide hormone that has been shown to participate in osteoclast activity and reabsorption of calcium and phosphorus through target organ comprised of the bone and kidney in mammals. CT is mainly produced in parafollicular cells (C cells) in the thyroid gland and is produced in a wide variety of other tissues [12] . Currently, CT is a therapeutic agent for treatment of bone diseases such as osteoporosis and Paget's disease [10, 16] . Expression of CT in tissue from the brain, prostate and uterus has been reported [3] [4] [5] , and this suggests that it has additional functions other than those for osteoclasts and the kidney. As supporting evidence for additional functions, the CT expression levels have been shown to be related with tumorigenicity of prostate cancer [15] and to be increased in the pregnant rat uterus during implantation [4] . Furthermore, treatment with antisense olignucleotide of CT mRNA severely impairs embryo implantation [18] .
In the past several years, the number of sense and antisense pair transcripts reported has sharply increased [7] . Due to the increase in the number of these studies, researchers have initiated investigations of not only of the localization of antisense transcripts but also of regulation of sense transcripts with their antisense transcripts in order to more fully understand the molecular interaction occurring in individual loci, cells and tissues. Changes in the expression levels of each non-coding RNA have been described for complex diseases such as cancer [1, 14, 17] and neurological diseases [11] .
However, little is known about the expression of CT sense and antisense pair transcripts during pre-and postnatal development. Hence, in the present study, we selected the above CT-related organs as tissues for a "transcriptomics" investigation and measured the amount of CT mRNA in the tissues over the course of mouse development. Furthermore, we examined the possible existence of CT antisense transcripts and the localization of CT mRNA as well as its antisense transcript in the target tissues.
MATERIALS AND METHODS

Animals:
Fourteen-day post-coitum (dpc), 17-dpc, newborn, 1-week-old and 8-week-old (adult) C57BL/6J mice (at least n=3 for each stage) at Riken Institute, Japan, were used for preparation of RNA and paraformaldehyde-fixed tissues. All procedures were performed according to the standards established by Riken Institute under the Guidelines for the Care and Use of Experimental Animals.
RNA extraction and reverse transcription: Total RNAs were extracted from the brain, kidney, heart, liver and testis at the developmental stages described above and from 17-dpc embryos using an RNeasy Mini Kit (Qiagen, Tokyo, Japan) according to the manufacturer's procedure and dissolved in nuclease-free water. The quality of the RNA samples thus obtained was examined by UV absorbance and agarose gel electrophoresis. To provide an internal control for comparison of the real-time PCR results in the present study, an aliquot of each RNA sample was mixed with an amount of RNA fragment synthesized from pEGFP-C1 vector (EGFP: enhanced green fluorescent protein, Invitrogen, Tokyo, Japan) to attain a final amount of 5  10 -5 pmol/10 g total RNA [6] , and the resulting mixture was subjected to synthesis of first-strand cDNA using a random hexamer primer (Takara Bio, Ohtsu, Japan) and Avian Myeloblastosis Virus-Reverse Transcriptase (Promega, Tokyo, Japan) according to the manufacturer's instructions. The resulting cDNAs were qualified by amplification of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sequence using a primer pair (Table 1) [9] based on the fact that GAPDH is known to be ubiquitously expressed in these tissues. The cDNAs were then stored at -20C until use for real-time PCR analysis. In order to prepare cDNA for examination of antisense RNA to CT mRNA, total RNA from 17-dpc embryos was subjected to synthesis of first-strand cDNA using the CTForward primer ( Table 1 ). The resulting sample was treated at 99C for 5 min and with RNaseA (Sigma-Aldrich Co., Tokyo, Japan) at a final concentration of 0.1 mg/ml for 1 hr at 37C and was then subjected to ethanol precipitation of cDNA. The cDNA thus obtained was stored at -20C until use for examination of the antisense RNA by PCR.
Quantitative real-time PCR: Primer pairs for CT and EGFP were designed using the Primer3 program (http:// frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) based on cDNA and genome sequences registered in a DNA database (Fig. 1) ; the sequences are described in Table 1 . Before performance of real-time PCR, the fragments amplified with the respective primer pairs from the cDNAs were sequenced to confirm that the primer pairs amplified the expected sequences.
An aliquot of the cDNA sample was mixed with real-time PCR Master Mix solution containing SYBR Green (Toyobo, Osaka, Japan) and 20 M of the primer pairs for the respective genes, as recommended by the manufacturer. The resulting mixtures were placed in an iCycler thermocycler (Bio-Rad, Hercules, CA, U.S.A.) under the conditions of 1 min at 95C and then 40 cycles each of 15 sec at 95C and 60 sec at 60C in order to perform real-time PCR. The data generated by the iCycler thermocycler were analyzed -5 pmol/10 g total RNA [6] ; the resulting mixture was subjected to synthesis of first-strand cDNA as described in MATERIALS AND METHODS. The cDNA sample was mixed with Master Mix solution containing SYBR Green (Toyobo) and 20M of the primer pairs for the respective genes and was then placed in an iCycler thermocycler (Bio-Rad) under the conditions of 1 min at 95C followed by 40 cycles each of 95C for 15 sec and 60C for 60 sec in order to perform real-time PCR. The values generated by the MJ Opticon Monitor TM Analysis Software Version 3.1 (Bio-Rad) were recalculated to obtain relative CT expression values by considering the EGFP expression value (internal control) to be 1.0 in the respective samples. The values thus obtained were subjected to statistical analysis using one-way ANOVA and Duncan's multiple range test. Bars indicate the means of the values, and the error bars indicate the standard error. Bar superscripts (a, b, c and d) indicate the significance (p<0.05) among the means of the respective stage samples for a given organ. A, B, C, D and E represent the brain, kidney, liver, heart and testis results, respectively. The 14-dpc, 17-dpc, newborn, 1-week-old and 8-week-old stages of development are indicated as 14 dpc, 17 dpc, NB, 1W and Adult, respectively. using the MJ Opticon Monitor TM Analysis Software Version 3.1 (Bio-Rad, Hercules, CA, U.S.A.). The values thus obtained were then normalized by referring to the value for EGFP in order to compare the values of the CT transcripts between samples. In addition, based on the ratio between the amplification efficiency of a CT cDNA fragment and that of an EGFP cDNA fragment obtained in a parallel experiment, the amounts of CT mRNA were calculated.
PCR for antisense RNA and sequencing of PCR products: The first-strand cDNA for the antisense RNA analysis was subjected to PCR using CT-Forward and CT-Reverse primers under the conditions of 7 min denaturation at 95C; 38 cycles of 30 sec at 95C, 30 sec at 60C and 90 sec at 72C; and then followed by extension at 72C for 10 min. The resulting samples were electrophoresed in 2% agarose gel to identify the amplified DNA fragments. When DNA fragments were detected in the agarose gel electrophoresis, they were subjected to sequencing to confirm whether they were derived from the CT locus.
Tissue fixation for in situ hybridization: The 14-dpc and 17-dpc mouse embryos were fixed with paraformaldehyde by immersing the embryos in 4% ice-cold paraformaldehyde-PBS solution (pH 7.4) for 24-36 hr. Newborn and 8-week mice, which had been euthanized with ether in accordance the guidelines of Riken, were first fixed in situ by perfusion of 4% (w/v in phosphate-buffered saline) ice-cold paraformaldehyde solution, and then the resulting organs/ tissues were excised to be further fixed overnight in the paraformaldehyde solution. The organs/tissues thus fixed were embedded in paraffin and then cut into 4-m thick sections. The sections were placed on glassslides and subjected to in situ hybridization.
RNA probes for in situ hybridization: Probes for CT mRNA and antisense RNA (Table 2) were synthesized using 120-nucleotide (nt) sequences specific for CT mRNA (NM_007587; Fig. 1 ). As a control RNA probe, a 120-nt LNE (Table 2) having no similarity with any of the mammalian sequences registered in the DDBJ DNA database was used in all the in situ hybridization experiments to verify that the hybridization system did not produce any non-specific hybridization signals [2] . In addition, a mouse protamine 1 antisense RNA probe was used as a positive control to verify that the mouse tissues could be used for in situ hybridization [2] . Single-strand DNA sequences were first chemically synthesized and subjected to PCR to generate double-strand DNA fragments. The resulting fragments were then subjected to in vitro transcription to produce DIG-labeled RNA, which was conducted by Tsukuba Genetech Laboratories (Tsukuba, Japan). The extent of the DIG-labeling in the fragments was confirmed to be the same using a NBT/BCIP detection system (Roche Diagnostics, Tokyo, Japan).
In situ hybridization: The procedure for in situ hybridization was the same as that reported previously [6] . Briefly, hybridization was performed in a solution containing 50% formamide, 2  SSC, 1.0 mg/ml tRNA, 1.0 mg/ml salmon sperm DNA, 1.0 mg/ml BSA, 1.0% SDS and 3.0 g/ml DIG-labeled RNA probe at 42C for 26-64 hr. Hybridization signals were visualized with the NBT/BCIP system and photographed through a microscope (Zeiss, Tokyo, Japan).
RESULTS AND DISCUSSION
Among the various CT-target organs mentioned in the INTRODUCTION section, brain, kidney, heart and testis tissues from mice at pre-and postnatal stages were subjected to measurement of CT mRNA and in situ hybridization for localization of mRNA (sense)/antisense RNA in each respective tissue. Additionally, cartilage, thyroid gland and ovary tissues from mice at prenatal stages were subjected to in situ hybridization.
Quantitative real-time PCR: Tissues from 14-dpc, 17-dpc, newborn, 1-week-old and 8-week-old (adult) C57BL/ 6J mice (at least n=3 for each stage) were used for preparation of RNA. The RNAs obtained from the tissues were processed to make cDNA samples as described in the MATERIALS AND METHODS. The respective organ cDNA samples from the mice at the various pre-and postnatal stages were independently prepared from at least three individual male mice and subjected to real-time PCR using the primer pair depicted in Fig. 1 .
The PCR results were processed as described in the MATERIALS AND METHODS. As shown in Fig. 2 , CT mRNA was found in all organs examined, i.e., the brain, kidney, liver, heart and testis. In the brain and kidney, the amount of CT mRNA was observed to roughly decrease as a function of mouse development. In the testis, elevation of the level of CT mRNA was found to have two phases: one peak was observed at 17-dpc and another was observed, at the 8 weeks of age. In the liver, expression was increased in the tissues from 14-dpc embryos to newborn mice and then decreased as a function of development. In the heart, high expressions were observed at 17-dpc and 8 weeks of age, although no expression was observed at 14 dpc.
The amounts of CT mRNA calculated based on the ratio of the amplification efficiency of the CT cDNA fragment to that of the EGFP cDNA fragment, 1.004 (data not shown), are summarized in Table 3 (see MATERIALS AND  METHODS) . Furthermore, assuming that the cells of the tissues examined contained 10 pg RNA per cell based on the data showing that 10 g of RNA could be prepared from 10 6 NIH3T3 cells (Qiagen, Tokyo, Japan), the number of CT mRNA molecules per cell was calculated for each tissue ( Table 3 ). The average number of CT mRNA molecules was shown to be less than one per cell; this indicates that CT is expressed in limited regions within these tissues.
Existence of CT antisense transcripts: In order to examine whether CT antisense transcripts were present in the tissues, total RNA from 17-dpc embryos was subjected to the modified RT-PCR as described in the MATERIALS AND METHODS. RT-PCR generated a fragment, the size of which was in good agreement with that (802 bp) expected from the genomic sequence (containing intron; Fig. 3A) . When the DNA fragment obtained from the "antisense" transcript was sequenced, the sequence was shown to be identical to the CT genomic sequence (data not shown). One may argue that the fragment was not derived from the RNA but that it was derived from residual genomic DNA Fig. 3 . Detection of CT antisense transcripts with a modified RT-PCR. First-strand cDNA for the antisense RNA analysis, prepared as described in MATERIALS AND METHODS, was subjected to PCR using CT-Forward and CT-Reverse primers under the conditions of 7 min denaturation at 95C; 38 cycles of 30 sec at 95C, 30 sec at 60C and 90 sec at 72C; and extension at 72C for 10 min. The resulting PCR sample was applied to 2% agarose gel electrophoresis with a 100-bp ladder size marker (SibEnzyme Ltd.). A representative electropherogram is shown in panel A. Column I is the size marker and column 2 is the sample. As a control, the total RNA sample was first treated with RNase A and then subjected to PCR to produce first-strand cDNA as described above, except that the number of PCR cycles was changed from 38 to 40. The resulting sample was electrophoresed as described above. A representative electropherogram is shown in panel B. Column 1 is the size marker, and column 2 is the sample.
remaining in the "total RNA" fraction. To investigate this possibility, an aliquot of the total RNA fraction was first treated with RNase A under the same conditions described above and was then subjected to RT-PCR; no fragments were generated in the RT-PCR (Fig. 3B) . These findings demonstrated that the CT antisense transcripts were generated in the 17-dpc embryo and that they were colinear with the genomic sequence in at least the region examined. Additionally, we carried out Northern blot analysis of the sense/antisense transcripts, and the results provided supportive evidence for existence of the antisense transcripts, although the signal levels were low (data not shown).
Gene expression sites in tissues: As shown in Fig. 4 , a 120-nt lambda phage sequence (LNE) probe (Table 3) , used as a negative control, produced no distinct signals, indicating that no hybridization-based interaction was detected between the RNA probes and cell materials among the tissues. In addition, the adult mouse testis, which was processed in the same manner as the other tissues in the present study, produced hybridization signals when probed with DIG-labeled mouse protamine 1 antisense RNA (data not shown); this served as a positive control for the present in situ hybridizations.
Based on the results of the above negative/positive controls for in situ hybridization, tissue sections for all organs with high expressions of CT mRNA in the developmental stages were subjected to in situ hybridization using CT probes. The CT sense and antisense transcripts were mainly localized in the mesencephalon of the 14-dpc brain, and the localization patterns of the sense and antisense transcripts appeared to be uniform, as indicated by arrows in Fig. 4A . In the 17-dpc kidney, the sense and antisense transcripts were observed to be rather uniform (Fig. 4B) . More precisely, the sense and antisense transcripts were more densely localized in the proximal and distal tubules (shown by arrows in the figure). In the 17-dpc heart (Fig. 4C) , newborn liver (Fig. 4E ) and adult testis (Fig. 4F) , the sense and antisense transcripts were shown to exist uniformly throughout the tissues, although the transcripts in the heart appeared to be densely localized in the intermediate wall of the papillary muscle between the aortic and pulmonary valve.
The bone cells in the ribs (shown by arrows in Fig. 4C ) and parafollicular cells (C cells) in the lobes of the thyroid gland (shown by arrows in Fig. 4D ), which were included in the 17-dpc embryo sections subjected to in situ hybridization, contained large amounts of the sense and antisense transcripts. In the adult ovary, the sense and antisense transcripts were detected in oocytes and follicular cells (shown by arrows in Fig. 4G ).
The present study first determined the amounts of CT sense transcripts in the brains, kidneys, livers, hearts and testis of mice at various developmental stages and revealed the localizations of the non-coding antisense RNA (transcripts) in the respective organs. In addition, existence of the sense and antisense transcripts was demonstrated in the cartilage cells of the costal cartilage, in oocytes and follicular cells and in C cells in the thyroid. Co-localization of the sense and antisense transcripts of the CT gene suggests that they may operate in regulatory networks during development; this is consistent with a previous study [18] indicating that the treatment of antisense oligonucleotide of CT mRNA caused severe impairment of embryo implantation. Taken together, these findings suggest that, like Xist/Tsix gene [8, 13] , CT antisense transcripts might be involved in control of CT gene expression.
Currently, many genes have been reported to produce sense and antisense transcripts in the mouse genome [7] and been listed in various databases (Ensemble Genome Brower, http://www.ensemble.org; FANTOM3, http:// f a n t o m 3 . g s c . r i k e n . g o . j p ; a n d N A T s D B , h t t p : / / natsdb.cbi.pku.edu.cn). Antisense transcripts with no protein-coding capacity are a general property of eukaryotic genomes; this indicates that antisense transcripts are important players in the new "molecular pipeline" within eukaryotic cells. However, CT has not previously been reported to be a gene known to produce both sense and antisense transcripts. This may indicate that the number of mouse genes producing both sense and antisense transcripts would increase if an extensive analysis is performed for the sense and antisense transcripts of genes.
